Strategic Thrusts Banner
Engineering CELLS,
   Engineering RESPONSES

HISTORY

2016 - Present

27 FEBRUARY 2017

BTI was awarded the Center of Innovation Award by Waters Corporation. By being part of the Centers of Innovation Program, BTI can tap on Waters’ analytical technologies and expertise to further advance the development of glyco-related biopharmaceuticals for the industry.

2011 - 2015

12-13 MARCH 2015

BTI commemorated 25 years of research excellence. To celebrate 25 years of achievements, a two-day Conference on “The Future of Biologics” was organized on 12 & 13 March at Suntec Singapore Convention & Exhibition Centre. BTI also had the 25th Anniversary Gala Dinner on 13 March at Conrad Centennial Singapore.

14 MARCH 2014

BTI spun off MiRXES, a company focused on developing novel blood based molecular diagnostic tests for non-invasive cancer detection and prognosis. MiRXES’ core capability is a class-leading qPCR technology which detects miRNA, a novel class of epigenetic regulator and biomarker, with high sensitivity and specificity.

12 FEBRUARY 2014

BTI signed two Memorandums of Understanding (MOUs) with KBSI and GRAST to advance collaboration between Singapore and South Korea in the field of glycomics in Asia. The MOUs will collectively increase the impact of both countries’ glycomics capabilities and establish them as leaders in Asia in glycomics research. The Guest of Honour, Mr Lim Chuan Poh, Chairman A*STAR and His Excellency Suh Chung-ha, Ambassador of Korea to Singapore were invited to witness the signing ceremony.

SKSG VIP photo History3

23 MAY 2013

Agilent Technologies Inc., the Glyco-MEV laboratory at the University of Rouen, in France, and BTI signed a memorandum of understanding to work together to develop tools to effectively analyze biologics and vaccines.

19 MAY 2013

VeriStem Technologies, a spin-off from BTI, has been awarded the Biospectrum Asia-Pacific Emerging Companies of the Year Award 2013.

13 DECEMBER 2012

The collaboration between scientists at BTI led by Prof Lam Kong-Peng, and clinician-scientists at National University Cancer Institute, Singapore (NCIS) and the Cancer Science Institute of Singapore (CSI Singapore) have identified FAIM, a molecule that typically prevents cell death, as a potential biomarker to identify an incurable form of cancer in the bone marrow. The research findings were published in Leukemia on 5 December 2012.

1 OCTOBER 2012

Professor Lam Kong Peng was appointed as the Executive Director of BTI.  

11 MAY 2012

BTI scientists have identified the molecular 'switch' that directly triggers the body's first line of defence against pathogens, more accurately known as the body's "innate immunity". The research findings were published in Proceedings of the National Academy of Sciences (PNAS) on 10 April 2012.

2006 - 2010

16 November 2010

Professor Lam Kong Peng (Scientific Director, BTI) was the first Singaporean to be honoured with the Arthur Kornberg Memorial Award by the Asia Pacific International Molecular Biology Network (A-IMBN).

  Professor Lam Kong Peng (left) receiving the medal from Professor Ken-ichi Arai, Founding President of A-IMBN, and former Dean of Tokyo University Medical School

29 MARCH 2010

20th Anniversary Symposium at Club Med Bintan


BTI 20th Anniversary Symposium at Club Med Bintan

28 September 2009

Professor Miranda Yap (Executive Director, BTI) received the President's Science and Technology Medal during the inaugural President's Science and Technology Awards (PSTA) ceremony held at the Istana.

 

Professor Yap receiving the President's Science and Technology Medal
from President S R Nathan

20 May 2009

BTI spun off VeriStem™ Technologies, a company focused on developing processes to enable safe stem cell therapies based on core technologies developed at BTI

2008 – 2009

BTI established research collaboration agreement with industry partners – F. Hoffman La-Roche (Switzerland), Avir Green Hills Biotechnology R&D (Austria), GSK Biologicals SA (Belgium) and International Flavors & Fragrances Inc (USA)

6 November 2008

Licensed manufacturing and sale rights for human embryonic stem cell monoclonal antibodies to Alexis Corporation (Switzerland) and Millipore Corporation (USA)

2006

Set up Biopreneur Labs to house small and medium enterprises (SMEs) or new operations from MNC in Singapore like ES Cell International Pte Ltd, SG Austria Pte Ltd, Rhapsody Biologics (S) Pte Ltd, Abbott Laboratories (S) Pte Ltd, and Mesoblast International SA (Singapore).

3 March 2006

BTI jointly established the Consortium for CHO Cell Genomics with the University of Minnesota (USA) and the Society for Biological Engineering (USA).

1st CHO Consortium Meeting

 

2003 - 2005

 

July 2005

Developed the Bioprocess Internship Programme to fulfill manpower needs of the biopharmaceutical industry in Singapore

19 – 21 April 2004

BTI organised the inaugural Singapore Biologics Manufacturing Conference with the Interlaken Conference Biotech Partners (Switzerland).

  Prof Miranda Yap at the first Singapore Biologics Manufacturing Conference

21 April 2004

BTI held its inaugural Open House at Biopolis. The Guest-of-Honour at the Commemoration Ceremony was Mr Philip Yeo, Chairman of A*STAR and Co-Chairman of the Singapore Economic Development Board (EDB).

Commemoration Ceremony

2003

Researchers from BTI and NUS established Immuno Biocare Pte Ltd.

November 2003

BTC became Bioprocessing Technology Institute (BTI), which is funded by the Agency for Science Technology and Research (A*STAR) through its Biomedical Research Council.

November 2003

BTC moved to Biopolis, which had its official opening ceremony on 29 October 2003.

BTC moved to the Centros Building in Biopolis

29 January 2003

BTI's Bioprocessing Manufacturing Technology Centre (BMTC) spun off as a commercial entity under A-Bio Pharma Pte Ltd, a biologics contract manufacturing company which undertakes process development and the commercial production of clinical grade materials

Opening Ceremony of the Biopharmaceutical Manufacturing Technology Centre's cGMP Facility

 

1995 - 2002

 

25 July 2002

As a joint effort with the Institute of Molecular and Cell Biology (IMCB), BTC helped to spin off MerLion Pharmaceuticals Pte Ltd (MerLion Pharma) which focused on drug discovery from natural products. MerLion Pharma was formed through the privatisation of the former Centre for Natural Product Research (CNPR), a unit in IMCB.

1999

BTC set up the Biopharmaceutical Manufacturing Technology Centre (BMTC) for GMP biologics manufacturing in Science Park II.

1998

Licensed "Supermedia" to Becton Dickinson

1998

BTC established Genset Singapore Biotechnology Pte Ltd, a joint venture company with Genset (France), which focused on oligos synthesis.

  Opening Ceremony for
Genset Singapore Biotech Pte Ltd

1997

BTC set up Incubator Unit at Science Park II to host the following young biotech companies:

  • Oculex Asia Pharmaceuticals Pte Ltd
  • Gene Singapore Pte Ltd
  • Specialty Laboratories Asia Pte Ltd
  • Genset Singapore Biotechnology Pte Ltd
  • Cell Transplants Singapore Pte Ltd
  • Biomedical Research and Support Services

BTC Incubator Unit

1995

BTU became the Bioprocessing Technology Centre (BTC), supported by the National Science and Technology Board (now A*STAR).

Transformed and Renamed as BTC

 

1990 - 1994

 

1990 – 1994

BTU served twin role of manpower training and providing contract services to local and overseas biotechnology companies such as Genelabs Diagnostics, Biocode Asia, DR Brommeli and Merial Asia.

Small and Large bioreactors

1990

Bioprocessing Technology Unit (BTU) was established and funded under the Biotechnology Competency Enhancement Programme administered by the Singapore Economic Development Board. The head of the unit was Professor Miranda Yap.

First Home at the Department of Chemical Engineering, NUS